About this study
This study looks at how well the experimental drug flotetuzumab works when given to children and young adults with relapsed or refractory acute myeloid leukemia. Flotetuzumab is experimental because it has not been proven to work in young patients with this type of AML. Although flotetuzumab has been tested in adults, it has not been approved for use by the FDA for adults or for children.
We are using flotetuzumab because it seems to work against cancer in test tubes and animals. This is called a Phase I study because the goal is to find the highest dose of flotetuzumab that we can give safely. If there is no improvement in your leukemia after 2 cycles of treatment, your treatment with flotetuzumab will be stopped.
Eligibility overview
- Younger than 21 years of age
- Diagnosed with recurrent or refractory acute myeloid leukemia (AML)
- Weigh more than 17kg
- Fully recovered from the acute toxic effects of all prior anti-cancer therapy